Skip to main content

Table 1 Assessment of methodological quality of the included RCTs by Jadad scoring criteria*

From: Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis

Trial

Randomized†

Double-blinded§

A description of withdrawals or dropouts

Jadad score

Inyang-Etoh PC, 2009

1

2

0

3

Borrmann S, 2001

2

2

1

5

Santos AT, 1979

1

2

1

4

McMahon JE, 1979

1

1

1

3

Katz N, 1979

1

2

1

4

Liu ZG, 1997

1

0

1

2

Song Y, 2006

1

2

0

3

Li YS, 2005

1

2

1

4

N'Goran EK, 2003

2

2

1

5

Utzinger J, 2000

2

2

1

5

Tian ZY, 1999

2

2

0

4

Huang AS, 1999

1

2

1

4

Song Y, 1998

1

2

1

4

Xu MS, 1997

1

2

1

4

Tian ZY, 1997

1

2

1

4

Wang JL, 1997

1

2

1

4

Xiao SH, 1996

1

2

0

3

Xiao SH, 1995

1

2

1

4

Xu MS, 2001

1

2

0

3

Cui JF, 2001

1

2

0

3

Sun MX, 2000

1

2

0

3

Zhang SJ, 2000

1

2

0

3

Yi ZH, 2000

1

2

1

4

Liu HY, 1999

1

2

0

3

Xu MS, 1998

2

2

0

4

Liu ZD, 1996

1

2

0

3

Xu MS, 1996

1

2

1

4

Wu LJ, 1995

1

2

1

4

Hou XY, 2008

1

2

1

4

  1. * Range 0~5 (the higher the Jadad score is, the higher the quality of study is).
  2. † Represents generation of allocation sequence.
  3. § Represents allocation concealment.